Skip to main content
. 2023 Mar 2;108(10):2865–2871. doi: 10.3324/haematol.2022.281552

Figure 1.

Figure 1.

Kaplan-Meier plots of event-free survival in COG P9407 trial. Event-free survival (EFS) in treatment-eligible infants estimated by Kaplan-Meier method as a function of: (A) KMT2A-G and KMT2A partner genes (11 treatment-eligible in category ‘unknown’ partner gene excluded); (B) age </>90 days in KMT2A-R overall (left), AAF1 (middle), and MLLT1 (right); (C) white blood cell (WBC) count </>50×109/L in KMT2A-R overall (left), MLLT1 (middle), and KMT2A-G (right); (D) male vs. female sex in KMT2A-R overall (left), and AAF1 (right); (E) central nervous system (CNS) status in KMT2A-R overall, and AAF1 (right). CNS1 (CNS-negative), CNS2 (positive cytomorphology but <5 WBC/µL), CNS3 (>5 WBC/µL and positive cytomorphology). (A-E) EFS calculated as time from diagnosis to first event (induction failure, relapse, secondary malignancy, remission death). Patients having no event were censored at last contact. Numbers of patients are indicated in the plots. P values calculated by log-rank test are at top right in the plots.